Published in J Dermatolog Treat on July 24, 2011
Effect of pill burden on dosing preferences, willingness to pay, and likely adherence among patients with type 2 diabetes. Patient Prefer Adherence (2013) 0.94
Patients' preferences for bone metastases treatments in France, Germany and the United Kingdom. Support Care Cancer (2014) 0.88
Preference for pharmaceutical formulation and treatment process attributes. Patient Prefer Adherence (2016) 0.75
Direct health care insurer and out-of-pocket expenditures of inflammatory bowel disease: evidence from a US national survey. Dig Dis Sci (2012) 1.93
Health-related workplace productivity measurement: general and migraine-specific recommendations from the ACOEM Expert Panel. J Occup Environ Med (2003) 1.85
Impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis. Kidney Int (2004) 1.68
Effect of patient exclusion criteria on the efficacy of erythropoiesis-stimulating agents in patients with cancer-related anemia. Oncologist (2005) 1.41
Epoetin alfa improves quality of life in patients with cancer: results of metaanalysis. Cancer (2004) 1.17
Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci (2011) 1.16
Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol (2010) 1.10
Direct medical costs of complications of diabetes in the United States: estimates for event-year and annual state costs (USD 2012). J Med Econ (2014) 1.01
Effect of pill burden on dosing preferences, willingness to pay, and likely adherence among patients with type 2 diabetes. Patient Prefer Adherence (2013) 0.94
Effects of a Website designed to improve the management of migraines. Headache (2006) 0.93
An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma. Leuk Lymphoma (2007) 0.93
Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives--an update. Ann N Y Acad Sci (2012) 0.91
Patient-based utilities for bipolar disorder-related health states. J Affect Disord (2005) 0.90
Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives. Ann N Y Acad Sci (2011) 0.90
Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: results from PHOENIX 2. J Dermatolog Treat (2010) 0.86
Disease and treatment burden of psoriasis: examining the impact of biologics. J Drugs Dermatol (2011) 0.86
Increased prevalence of psychiatric disorders and health care-associated costs among patients with moderate-to-severe psoriasis. J Drugs Dermatol (2011) 0.86
Psychometric evaluation of the functional assessment of HIV Infection (FAHI) questionnaire and its usefulness in clinical trials. Qual Life Res (2010) 0.85
Effects of etravirine versus placebo on health-related quality of life in treatment-experienced HIV patients as measured by the functional assessment of human immunodeficiency virus infection (FAHI) questionnaire in the DUET trials. HIV Clin Trials (2010) 0.85
Quality of care measures for migraine: a comprehensive review. Dis Manag (2007) 0.84
Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial. J Drugs Dermatol (2013) 0.83
Ustekinumab dosing, persistence, and discontinuation patterns in patients with moderate-to-severe psoriasis. J Dermatolog Treat (2014) 0.82
Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis. J Dermatolog Treat (2011) 0.82
Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection. AIDS (2012) 0.81
Gastroenterologists' Views of Shared Decision Making for Patients with Inflammatory Bowel Disease. Dig Dis Sci (2015) 0.81
Quality measure attainment in patients with type 2 diabetes mellitus. Am J Manag Care (2014) 0.81
Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA. Pharmacoeconomics (2010) 0.81
Patient preferences for reducing toxicities of treatments for gastrointestinal stromal tumor (GIST). Patient Prefer Adherence (2011) 0.81
Impact of ustekinumab on health-related quality of life in Japanese patients with moderate-to-severe plaque psoriasis: results from a randomized, double-blind, placebo-controlled phase 2 / 3 trial. J Dermatol (2012) 0.80
Variations in care: a retrospective database analysis of healthcare utilization patterns for patients with inflammatory bowel disease. J Med Econ (2014) 0.79
Epoetin alfa's effect on left ventricular hypertrophy and subsequent mortality. Int J Cardiol (2005) 0.79
Consumer preferences for household water treatment products in Andhra Pradesh, India. Soc Sci Med (2012) 0.79
Ustekinumab improves health-related quality of life in Korean and Taiwanese patients with moderate to severe psoriasis: results from the PEARL trial. J Drugs Dermatol (2012) 0.78
The Employee Absenteeism Costs of Rheumatoid Arthritis: Evidence From US National Survey Data. J Occup Environ Med (2015) 0.78
The employee absenteeism costs of inflammatory bowel disease: evidence from US National Survey Data. J Occup Environ Med (2013) 0.78
Cost utility analysis based on a head-to-head Phase 3 trial comparing ustekinumab and etanercept in patients with moderate-to-severe plaque psoriasis: a Canadian perspective. Value Health (2011) 0.77
Migraine headache misconceptions: barriers to effective care. Pharmacotherapy (2004) 0.77
Adjusting for comorbidities in cost of illness studies. J Med Econ (2014) 0.77
The direct healthcare insurer and out-of-pocket expenditures of psoriasis: evidence from a United States national survey. J Dermatolog Treat (2011) 0.77
Budget impact analysis of ustekinumab in the management of moderate to severe psoriasis in Greece. BMC Dermatol (2012) 0.76
Reliability and validity of the migraine therapy assessment questionnaire. Headache (2002) 0.76
Outcome measures for pharmacoeconomics education. Pharmacoeconomics (2004) 0.75
Cost-efficacy comparison of biological therapies for patients with moderate to severe psoriasis in Japan. J Dermatolog Treat (2012) 0.75
Economic simulation of canagliflozin and sitagliptin treatment outcomes in patients with type 2 diabetes mellitus with inadequate glycemic control. J Med Econ (2014) 0.75
An Assessment of the AGA and CCFA Quality Indicators in a Sample of Patients Diagnosed with Inflammatory Bowel Disease. J Manag Care Spec Pharm (2015) 0.75